Content about Allergic rhinitis

April 18, 2014

Merck on Thursday announced that the Food and Drug Administration has approved Ragwitek (short ragweed pollen allergen extract) tablet for sublingual use (12 Amb a 1-U).

WHITEHOUSE STATION, N.J. — Merck on Thursday announced that the Food and Drug Administration has approved Ragwitek (short ragweed pollen allergen extract) tablet for sublingual use (12 Amb a 1-U). Ragwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis. Ragwitek is approved for use in adults ages 18 years through 65 years. 

April 15, 2014

The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets.

SILVER SPRING, Md. — The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets. 

The proposed OTC use is "temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Nasal congestion, runny nose, itchy, watery eyes, sneezing, itching of the nose.” The applicant proposes to label the product for OTC use in adults 18 years and older. 

April 15, 2014

Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use.

WHITEHOUSE STATION, N.J. — Merck announced that the Food and Drug Administration has approved Grastek (Timothy grass pollen allergen extract) tablet for sublingual use. The drug is an allergen extract used for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. It is approved for use in persons ages 5 years through 65 years of age.

April 2, 2014

Greer Labs, a developer and provider of allergy immunotherapy products and services, announced that the Food and Drug Administration has approved Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass mixed pollens allergen extract) sublingual allergy immunotherapy tablet.

LENOIR, N.C. — Greer Labs, a developer and provider of allergy immunotherapy products and services, announced that the Food and Drug Administration has approved Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass mixed pollens allergen extract) sublingual allergy immunotherapy tablet.

March 26, 2014

Springtime allergy season may be delayed a few weeks this year, kicking into high gear in early April as opposed to late March due to a 2013-2014 winter characterized by extremely low temperatures and heavy snow storms.

Springtime allergy season may be delayed a few weeks this year, kicking into high gear in early April as opposed to late March due to a 2013-2014 winter characterized by extremely low temperatures and heavy snow storms. 

February 18, 2014

Retailers were preparing for the imminent launch of Chattem’s Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) last month, clearing out quite a bit of shelf space for the new allergy remedy.

Retailers were preparing for the imminent launch of Chattem’s Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) last month, clearing out quite a bit of shelf space for the new allergy remedy.

(For the full category review, including sales data, click here.)

January 27, 2014

The Food and Drug Administration will hold a public meeting of the Allergenic Products Advisory Committee on Tuesday to determine the safety and efficacy of Ragwitek, a short ragweed pollen allergen extract tablet for sublingual use.

ARLINGTON HEIGHTS, Ill. — The Food and Drug Administration will hold a public meeting of the Allergenic Products Advisory Committee on Tuesday to determine the safety and efficacy of Ragwitek, a short ragweed pollen allergen extract tablet for sublingual use, which is manufactured by Merck and indicated for immunotherapy for diagnosed ragweed pollen induced allergic rhinitis, with or without conjunctivitis.

November 8, 2013

A study being presented this week at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology found hay fever is more prevalent in children living in the southeastern and southern states, ACAAI announced Friday.

BALTIMORE — A study being presented this week at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology found hay fever is more prevalent in children living in the southeastern and southern states, ACAAI announced Friday.

October 18, 2013

Chattem recently announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies. And that means by spring 2014, there will be another allergy powerhouse alongside Allegra, Claritin and Zyrtec.

Chattem recently announced that the Food and Drug Administration approved Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) as an over-the-counter treatment for seasonal and year-round nasal allergies. And that means by spring 2014, there will be another allergy powerhouse alongside Allegra, Claritin and Zyrtec. 

May 30, 2013

Children in the United States are more likely to experience allergies than those in other countries, according a new study.

CHICAGO — Children in the United States are more likely to experience allergies than those in other countries, according to a new study.

May 8, 2013

Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.

WHITEHOUSE STATION, N.J. — Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.

Merck said the Food and Drug Administration accepted a regulatory application for its ragweed pollen sublingual allergy immunotherapy tablet. Ragweed, also known as Ambrosia artemisiifolia, is a major cause of seasonal allergies in the United States. Merck also submitted an application for a similar drug, for Timothy grass pollen allergies, in March.

April 3, 2013

The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said.

MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said Wednesday.

Tris announced the approval of Karbinal ER (carbinoxamine maleate) extended-release oral suspension in the 4 mg-per-five milliliter strength. The company said the drug was the first sustained-release histamine receptor blocking agent for seasonal and perennial allergic rhinitis in children 2 and older.

February 25, 2013

As spring approaches, people with allergies can blame global warming for some of their suffering, according to the American College of Allergy, Asthma and Immunology. Weather conditions have a significant effect on the levels of pollen and mold in the air, which affects the severity of allergies.

As spring approaches, people with allergies can blame global warming for some of their suffering, according to the American College of Allergy, Asthma and Immunology. Weather conditions have a significant effect on the levels of pollen and mold in the air, which affects the severity of allergies.

That suggests mold allergens could be particularly prominent this spring given the extent of drought across the United States — dry and hot weather lifts molds from the soil to be carried by the air. In addition to tree pollen, springtime mold contributes to hay fever.